IPSEN |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113 EUR | +0.62% |
|
+4.24% | +4.73% |
| Apr. 24 | IPSEN : Better-than-expected Q1; guidance unchanged |  |
| Apr. 24 | Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024 |
Presenter SpeechDavid Loew (Executives)Good afternoon, and good morning, everybody. It's my gr...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-27
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
113
EUR
Average target price
125.1
EUR
Spread / Average Target
+10.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.73% | 9.96B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- IPN Stock
- News Ipsen
- Transcript : Ipsen S.A. - Analyst/Investor Day
